Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Barusiban - Ferring Pharmaceuticals

Drug Profile

Barusiban - Ferring Pharmaceuticals

Alternative Names: FE 200 440

Latest Information Update: 15 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Oligopeptides; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility
  • Discontinued Preterm labour

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Jan 2018 Barusiban is still at phase II development stage for Female infertility in Australia, Belgium, Canada, Czech Republic, Poland and Spain (SC)
  • 15 Jan 2018 Discontinued - Phase-II for Preterm labour (Prevention) in Finland, Lithuania, Poland, Romania, Czech Republic, Belgium (IV) (Indication not listed on Ferring pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top